Preliminary evidence suggests that genetic testing for susceptiblygenes for PCC/PGL should include the FH gene andthat patients with HLRCC should be screened for PCC/PGL. This evidence concerns the gene FH and hereditary leiomyomatosis and renal cell cancer.